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Transforming growth factor-β/Smad3 
signalling regulates inflammatory responses  
in a murine model of contact hypersensitivity
Transforming growth factor (TGF)-β is an important mod-
ulator of immune functions and cellular responses, such 
as differentiation, proliferation, migration and apoptosis. 
The Smad proteins, which are intracellular TGF-β signal 
transducers, and mediate most actions of TGF-β, were 
studied in a murine model of contact hypersensitivity. The 
expression of proinflammatory [interleukin (IL)-1β, tumour 
necrosis factor-α, IL-6], Th2 (IL-4) and Th17 type cytokines 
(IL-17), as well as regulatory components (TGF-β, Foxp3), 
increased significantly at the mRNA level in the skin of 
oxazolone-treated Smad3–/– mice when compared with 
wild-type controls. The expression of Th1 type cytokine 
interferon-γ and chemokines CXCL9 and CXCL10 was, 
however, unaffected by the lack of Smad3. Also Th2 type 
chemokines CCL24, CCL3 and CXCL5 were increased in 
the skin of Smad3–/– mice compared with wild-type mice. 
Br J Dermatol 2008; 159:546–54.
Loss-of-function polymorphisms in the 
filaggrin gene are associated with an 
increased susceptibility to chronic irritant 
contact dermatitis: a case–control study
Polymorphisms in the FLG gene were studied to deter-
mine whether they contributed towards susceptibility to 
chronic irritant contact dermatitis (CICD). In a case–control 
study, the FLG polymorphisms R501X and 2282del4 were 
determined in 296 patients with CICD; 217 apprentices 
in vocational training for high-risk occupations for CICD 
were chosen as controls. Heterozygotes for R501X and 
2282del4, FLG null alleles, were more frequent among 
patients with CICD (12.5%) compared with controls (6.9%), 
resulting in an odds ratio of 1.91 (95% confidence interval 
1.02–3.59). This showed that FLG null alleles are associat-
ed with increased susceptibility to CICD; whether the FLG 
null allele is an independent risk factor needs further study. 
Br J Dermatol 2008; 159:621–7.
Treatment of rosacea with intense pulsed light: 
significant improvement and long-lasting results
Intense pulsed light (IPL) was used to treat stage I rosa-
cea (flushing, erythema and telangiectasia). The treatment 
employed was IPL 515–1200 nm, with a 560 nm cut-off 
filter. The fluence range was 24–32 J cm–2. Four treatments 
were administered on the face at 3-week intervals. Thirty-
four patients were treated, 25 women and nine men, mean 
age 47 years. After four treatments the mean reduction of 
the erythema index was 39% on the cheeks (P < 0.001) and 
22% on the chin (P < 0.001). This was confirmed by photo-
graphic assessment where erythema improved by 46% and 
telangiectasia by 55% (P < 0.001). The severity of rosacea 
was reduced on average by 3.5 points on a 10-point visu-
al analogue scale. Patients’ and physicians’ assessments 
of the overall improvement of rosacea were similar: more 
than 50% improvement was noticed in 73% and 83% of 
patients, respectively (P < 0.001). These results were sus-
tained at 6 months. Side-effects were minimal and self-lim-
iting. Br J Dermatol 2008; 159:628–32.
Polymorphic light eruption and skin cancer 
prevalence: is one protective against the other?
Because there is increased immune surveillance and 
resistance to immune suppression following exposure to 
ultraviolet radiation in polymorphic light eruption (PLE) one 
might expect a protective effect of PLE against skin cancer 
(SC) and, conversely, a reduced risk of PLE among patients 
with SC. A prospective case–control study was undertaken 
comprising 214 patients with SC with 210 sex- and aged-
matched controls and 100 patients with PLE and 155 sex- 
and aged-matched controls. Each participant answered 
a questionnaire aimed at establishing personal and fam-
ily history of SC and photodermatoses. The prevalence of 
PLE in people with SC was 7.5%, compared with 21.4% 
for controls (P < 0.001). The prevalence of SC in patients 
with PLE was 4%, compared with 7.1% for controls. The 
immunological basis of PLE may therefore confer protec-
tion against SC. Br J Dermatol 2008; 159:697–702.
Is there a relationship between homocysteine 
and vitiligo? A pilot study
The aim of this study was to determine the level of homo-
cysteine (Hcy) in the blood of patients with vitiligo as a first 
step in revealing if it had any relation to the pathogenesis of 
vitiligo and consequently if this would have an impact on 
its management. Twenty-six patients of both sexes with viti-
ligo (mean ± SD age 31.4 ± 8.1 years) and 26 age-matched 
healthy controls were included in this study. After exclud-
ing factors that may affect serum Hcy level, blood samples 
from patients and controls were obtained for Hcy determi-
nation by enzyme immunoassay. The mean serum level of 
Hcy was significantly higher in patients with vitiligo than in 
controls (P < 0.001). The Hcy level was significantly higher 
in male than in female patients (P < 0.001) and in male 
than in female controls (P < 0.001). Hcy level was relat-
ed to the activity of vitiligo. The authors concluded that 
elevated Hcy level may be a factor precipitating vitiligo in 
pre disposed individuals. Br J Dermatol 2008: 159:726–30.
